Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Does how you start a glucose monitor matter? new study says maybe

NCT ID NCT05928572

Knowledge-focused Sponsor: Holly Willis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 159 adults with type 2 diabetes to see if the way they are introduced to a continuous glucose monitor (CGM) affects their blood sugar control. One group received a nutrition-focused approach, while the other used a self-directed method. The main goal was to measure time in range—the percentage of time blood sugar stays between 70 and 180 mg/dL. The study also examined diet quality and what happens when CGM use is paused for four months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitor (CGM) initiation approach
What this could lead to
If successful, this could show that a nutrition-focused introduction to CGM helps people with type 2 diabetes better manage their blood sugar levels.
What could go wrong
This is a small, completed study comparing two educational approaches, not testing a new drug or device. Results may not apply to everyone with type 2 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

159 people

The number who actually took part.

Started

Jul 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults \>18 years of age * T2D diagnosis * HbA1c 7.0%-10.0% based on point-of-care test at screening * Taking no diabetes medication or taking stable-dose diabetes medication(s) for at least 30 days; willing to maintain stable diabetes medication regimen for the duration of the study * Has a personal cellular-plan or wifi-connected smartphone that is compatible with required CGM apps and which will be consistently available for duration of the study * Has not used a personal CGM system within 90 days * Willing and able to wear CGM and use the associated CGM mobile apps throughout the duration of the study * Willing and able to make diet/lifestyle modifications in response to CGM data * Able to read and understand English * Able to attend study visits and complete the requirements of study Exclusion Criteria: * Currently taking or planning to take any form of insulin, sulfonylureas, meglitinides, or other anti-hyperglycemic diabetes medication that carry a known hypoglycemia risk * Has used a personal CGM in the 90 days prior to consent * Known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin * Skin conditions that are not compatible with CGM wear * Intended use of \> 4g acetaminophen/day or hydroxyurea during the study * Planning to become pregnant; pregnant; or lactating * Current participation in another interventional clinical trial * Unsuitable for participation due to any other cause, including but not limited to significant comorbidities, as determined by Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • HealthPartners Institute dba International Diabetes Center

    Minneapolis, Minnesota, 55416, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.